New drug cocktail may boost stem cell transplant success in blood cancer

NCT ID NCT01453101

First seen Apr 22, 2026 · Last updated Jun 18, 2026 · Updated 11 times

Summary

This study tested whether adding the drug bortezomib to the standard chemotherapy before a donor stem cell transplant could help people with multiple myeloma live longer without their cancer getting worse. Fifty-four adults received the new drug combo. The main goal was to see if this approach improved the time until the cancer progressed or the patient died, compared to past results with the standard two-drug regimen.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • John Theurer Cancer Center at Hackensack University Medical Center

    Hackensack, New Jersey, 07601, United States

Conditions

Explore the condition pages connected to this study.

Standardized tags

Added by Cure My Disease

We match each trial to standard medical vocabularies so it's findable however the registrant phrased it. These tags are added by us and may differ from the conditions listed above.

Disease matches (MONDO)

plasma cell myeloma

MeSH topics

Multiple Myeloma